shouyebanner1-454.jpg banner-shoujishouye1.jpg

Let Cell Therapies Eradicate Cancer Cells

See More

shouyebanner2-287.jpg banner-shoujishouye2.jpg

Neukio Biotherapeutics on a New Mission

shouyebanner3-907.jpg banner-shoujishouye3.jpg

Building new future in cell therapy

About Neukio

Neukio Biotherapeutics focuses on development of next generation allogenic cell therapies via the iPSC-CAR-NK axis, through internal discovery and external collaboration, with emphasis on innovative immuno-oncology products.


million dollars raised of financing


Corporate established


square meters of R&D and manufacturing facilities

NK Cell

Natural killer (NK) cells are key players in our immune system. Derived from bone marrow lymphoid stemcells, NK cells are mainly distributed in bone marrow, peripheral blood, liver, spleen, lung, and lymph nodes. Unlike T- and B-lymphocytes, NK cells can recognize and kill a broad spectrum of ‘non-self’ cells, including tumor cells and virally infected cells, without the need for pre-immune activation or sensitization.



Commercial production

Solid tumor


About Founder

Richard Liqun Wang Ph. D., MBA.

Founder, Chairman and CEO, Neukio Biotherapeutics

Former positions held: 

-   VP & CTO, Fosun Pharma

-   Founding CEO of Fosun Kite Biotech, completed tech transfer, registration trial and market authorization application for Yescarta in China (the first CAR-T product) in less than three years

-   COO of CBMG (Cellular Biomedical Group), managed production and clinical trials of stem cell and CAR-T therapies

-   Head of Operations, GSK R&D Center in China

-   Director of Alliance, Externalization and Portfolio Management, AstraZeneca Innovation Center China

-   Associate Director, Discovery Portfolio and Project Management, Bristol-Myers Squibb USA

-   Group Leader & Principal Scientist, Procter & Gamble Pharmaceuticals, USA